Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Non-Small Cell Lung Cancer

Trial Information

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on you and your lung cancer to see which is better at preventing the cancer from coming back.

Disease Characteristics:

• Diagnosis of stage IB-IIIA (T2-3 N0, T1-3 N1, T1-3 N2) non-small cell lung cancer (NSCLC)
• Patients with stage IB disease must have tumors measuring > 4 cm
• Must have undergone complete resection of NSCLC within the past 6-12 weeks
• Accepted types of resection include any of the following:
  • Lobectomy
  • Sleeve lobectomy
  • Bilobectomy
  • Pneumonectomy
• No resection by segmentectomy or wedge resection

For more information please go to http://www.valleyhealth.com/VH_ps_Oncology Clinical.asp

Cheryl Parish, RN, Manager, Oncology Clinical Trials
The Valley Hospital/Valley Health System
The Daniel and Gloria Cancer Center
One Valley Health Plaza
Paramus, NJ 07652
Phone: 201-634-5792
EMail: cparish@valleyhealth.com

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.